author-photo

Joan Carles

Hebron University
Autonomous University of Barcelona

307

Papers

8844

Citations

Citation Trend

Filter By

Papers (214) Sort By

Journal Conference Others

612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
PARP inhibitors in advanced prostate cancer: when to use them?

2021 Endocrine-related Cancer
Show All
- Source
- Cite
- Save
Citations (1)
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.

2021 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (9)
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

2021
Show All
- Source
- Cite
- Save
Citations (0)
73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.

2021 Oncogene
Show All
- Source
- Cite
- Save
Citations (0)
MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Economia, Territori i Sostenibilitat

2020
- Llurdés Coit
- Joan Carles
Show All
- Source
- Cite
- Save
Citations (0)
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.

2020 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (16)